RDGLClinical Trials•globenewswire•August 14, 2025 at 12:30 PM

Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA

Sentiment:Negative (-70)

Summary

Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 14, 2025 by globenewswire